Alamar Biosciences Expands Neurodegenerative Disease Partnership
FREMONT, California, August 10, 2026 Alamar Biosciences, Inc. announced an expansion of its strategic partnership with the Alzheimer’s Disease...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
FREMONT, California, August 10, 2026 Alamar Biosciences, Inc. announced an expansion of its strategic partnership with the Alzheimer’s Disease...
AMSTERDAM, Netherlands, June 2, 2026 Royal Philips has received U.S. FDA 510(k) clearance and CE Mark approval for Elevate...
FREMONT, California, USA, June 2, 2026 Alamar Biosciences has unveiled its NULISA™ Dried Blood Spot (DBS) Extraction Kit, a...
DUBLIN, Ireland, April 9, 2026 Jazz Pharmaceuticals plc has announced the presentation of six scientific abstracts, including one oral...
